West China Hospital COVID-19 vaccine

West China Hospital COVID-19 vaccine
Vaccine description
TargetSARS-CoV-2
Vaccine typeProtein subunit
Clinical data
Routes of
administration		Intramuscular
Identifiers
DrugBank

West China Hospital COVID-19 vaccine is a COVID-19 vaccine candidate developed by Jiangsu Province Centers for Disease Control and Prevention, West China Hospital and Sichuan University.

Clinical trials

In August 2020, WestVac Biopharma started phase I clinical trials with 168 participants in China.[1]

In November, WestVac Biopharma started phase II clinical trials with 960 participants in China[2] In February 2021, WestVac Biopharma started phase IIb clinical trials with 4,000 participants in China. Later, WestVac Biopharma is no longer on phase IIb clinical trial.[3]

In June 2021, WestVac Biopharma started phase III trials with 40,000 participants including Indonesia, Kenya, and the Philippines.[4]

Children and adolescents trials

In August 2021 WestVac Biopharma started phase I/II trials with 600 participants for children and adolescents aged 6-17.[5]

References

  1. ↑ "Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)". clinicaltrials.gov. United States National Library of Medicine. 8 February 2021. Retrieved 20 March 2021.{{cite journal}}: CS1 maint: url-status (link)
  2. ↑ "A Phase II Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells)". clinicaltrials.gov. United States National Library of Medicine. Retrieved 20 March 2021.{{cite web}}: CS1 maint: url-status (link)
  3. ↑ "Phase IIb Clinical Trial of Recombinant Novel Coronavirus Pneumonia (COVID-19) Vaccine (Sf9 Cells)". clinicaltrials.gov. United States National Library of Medicine. Retrieved 20 March 2021.{{cite web}}: CS1 maint: url-status (link)
  4. ↑ "A Global Phase III Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells)". clinicaltrials.gov. United States National Library of Medicine. Retrieved 15 May 2021.{{cite web}}: CS1 maint: url-status (link)
  5. ↑ "Phase I/II Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells) in Children and Adolescents". clinicaltrials.gov. United States National Library of Medicine. Retrieved 20 August 2021.{{cite web}}: CS1 maint: url-status (link)


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.